Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ONS 44th Annual Congress /
How genetic testing is guiding the use of PARP inhibitors

11th - 14th Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.05.19
Views: 3041

Suzanne Mahon - Saint Louis University, Missouri, USA

Suzanne Mahon speaks to ecancer at ONS 2019 about how genetic testing is guiding the use of PARP inhibitors in treating patients with breast or ovarian cancer. 

She discusses whether PARP inhibitors could potentially be used to treat patients with inherited mutations other than BRCA, such as ATM or PALB2.

Suzanne concludes with the reminder that genetic testing - while very useful for determining the best treatment - may have other consequences for the individuals being tested and their families.

This programme has been supported by an unrestricted educational grant from Pfizer. 

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation